| Literature DB >> 33304989 |
Simona Silenzi1, Giancarla Scalone1, Luca di Vito1, Luca Mariani1, Chiara Fraccaro2, Francesco Travaglini1, Pierfrancesco Grossi1.
Abstract
BACKGROUND: Increasing attention is being given to the rational use of invasive procedures. In this study, we aimed to evaluate, among patients referred for coronary angiography, the appropriateness of cardiac catheterization according to the Appropriate Use Criteria (AUC) for diagnostic catheterization and to examine the relationship between the appropriateness and the presence of obstructive coronary artery disease (CAD) and revascularization.Entities:
Keywords: Appropriate use; Coronary angiography; Coronary artery disease; Percutaneous coronary interventions
Year: 2020 PMID: 33304989 PMCID: PMC7711284 DOI: 10.1016/j.ijcha.2020.100677
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Baseline characteristics of the study’s population.
| Characteristics | All Cases (n = 1188) |
|---|---|
| Age (years – mean ± standard deviation) | 68 ± 12 |
| Sex: Female (%) | 342 (28.8) |
| Sex: Male (%) | 846 (71.2) |
| Hypertension history (%) | 998 (84.0) |
| Diabetes mellitus (%) | 352 (29.6) |
| Hypercholesterolemia (%) | 902 (75.9) |
| Tobacco Use: Current (%) | 305 (25.7) |
| Tobacco Use: Past (%) | 291 (24.5) |
| Previous Revascularization (%) | 219 (18.4) |
| Previous PCI (%) | 161 (13.6) |
| Previous CABG (%) | 35 (2.9) |
| Previous PCI and CABG (%) | 23 (1.9) |
| Previous MI (%) | 234 (19.7) |
| CHF (%) | 272 (22.9) |
| Total Cholesterol, mg/dl (mean ± standard deviation) | 195.4 ± 51.7 |
| HDL Cholesterol mg/dl (mean ± standard deviation) | 40.2 ± 9.9 |
| LDL Cholesterol, mg/dl (mean ± standard deviation) | 118.3 ± 29.1 |
| Triglyceride, mg/dl (mean ± standard deviation) | 127.5 ± 46.3 |
| Serum Creatinine, mg/dl (mean ± standard deviation) | 1.25 ± 1.00 |
PCI percutaneous coronary intervention; CABG coronary artery bypass grafting; MI myocardal infarction; CHF congestive heart failure; HDL high density lipoprotein; LDL low density lipoprotein.
Indications for coronary angiography of the entire study population according to the appropriate use criteria stratified by appropriateness.
| Indication | All Cases N = 1188 | Appropriate n = 1017 (85.6%) | Uncertain n = 134 (11.3%) | Inappropriate n = 37 (3.1%) | P Value* |
|---|---|---|---|---|---|
| STEMI or suspected STEMI (%) | 330 (27.8) | 330 (32.4) | - (0) | - (0) | <0.0001 |
| Unstable Angina/NSTEMI (%) | 363 (30.6) | 363 (35.7) | - (0) | - (0) | <0.0001 |
| Suspected CAD: No Prior Noninvasive Testing (%) | 33 (2.8) | 13 (1.3) | 9 (6.7) | 11 (29.7) | <0.0001 |
| Suspected CAD: Prior Noninvasive Testing | 150 (12.6) | 56 (5.5) | 85 (63.5) | 9 (24.4) | <0.0001 |
| FFR and IVUS (%) | 24 (2.0) | 18 (1.8) | 6 (4.5) | - (0) | 0.1348 |
| Known Obstructive CAD (%) | 76 (6.4) | 47 (4.6) | 19 (14.2) | 10 (27.0) | <0.0001 |
| Arrhythmias (%) | 37 (3.1) | 21 (2.1) | 13 (9.7) | 3 (8.1) | <0.0001 |
| Preoperative Coronary evaluation for Noncardiac Surgery in Stable Patients | 5 (0.4) | - (0) | 1 (0.7) | 4 (10.8) | <0.0001 |
| Valvular Disease (%) | 45 (3.8) | 44 (4.3) | 1 (0.7) | - (0) | 0.0177 |
| Cardiomyopathies (%) | 125 (10.5) | 125 (12.3) | - (0) | - (0) | <0.0001 |
STEMI ST-elevation myocardial infarction; NSTEMI Non-ST elevation myocardial infarction; CAD coronary artery disease; FFR fractional flow reserve; IVUS intravascular ultrasound.
Indications for coronary angiography according to the appropriate use criteria and clinical characteristics of patients with suspected coronary artery disease (CAD subgroup), stratified by appropriateness.
| Indications and Characteristics | All Cases N = 1018 | Appropriate n = 848 (83.3%) | Uncertain n = 133 (13.1%) | Inappropriate n = 37 (3.6%) | P Value* |
|---|---|---|---|---|---|
| STEMI or suspected STEMI %) | 330 (32.4) | 330 (100) | 0 (0%) | 0 (0%) | <0.0001 |
| Unstable Angina/NSTEMI (%) | 363 (35.7%) | 363 (100) | 0 (0%) | 0 (0%) | <0.0001 |
| Suspected CAD: No Prior Noninvasive Testing (%) | 33 (3.2) | 13 (39.4) | 9 (27.3%) | 11 (33.3%) | <0.0001 |
| Suspected CAD: Prior Noninvasive Testing | 150 (14.7) | 56 (37.3%) | 85 (56.7%) | 9 (6%) | <0.0001 |
| FFR and IVUS (%) | 24 (2.4) | 18 (75%) | 6 (25%) | 0 (0%) | 0.2699 |
| Known Obstructive CAD (%) | 76 (7.5) | 47 (62%) | 19 (25%) | 10 (13%) | <0.0001 |
| Arrhytmias (%) | 37 (3.6) | 21 (56.7%) | 13 (35.2%) | 3 (8.1%) | <0.0001 |
| Preoperative Coronary evaluation for Noncardiac Surgery in Stable Patients (%) | 5 (0.5) | 0 (0%) | 1 (20%) | 4 (80%) | <0.0001 |
| Age (years - mean ± standard deviation) | 68 ± 12.2 | 68.4 ± 12.5 | 65.8 ± 9.3 | 64.7 ± 10.3 | <0.0001 |
| Sex: Female (%) | 296 (29.1) | 252 (29.7) | 33 (24.8) | 11 (29.7) | 0.3150 |
| Sex: Male (%) | 722 (70.9) | 596 (70.3) | 100 (75.2) | 26 (70.3) | 0.3150 |
| Hypertension history (%) | 873 (85.8) | 736 (86.8) | 108 (81.2) | 29 (87.9) | 0.0346 |
| Diabetes mellitus (%) | 307 (30.2) | 264 (31.1) | 35 (26.3) | 8 (24.2) | 0.1301 |
| Hypercholesterolemia (%) | 815 (80.2) | 694 (81.8) | 93 (69.9) | 28 (84.8) | 0.0015 |
| Tobacco Use:Current (%) | 282 (27.8) | 244 (28.8) | 27 (20.3) | 11 (33.3) | 0.0878 |
| Tobacco Use: Past (%) | 255 (25.1) | 215 (25.4) | 33 (24.8) | 7 (21.2) | 0.6163 |
| Previous Revascularization (%) | 215 (21.2) | 183 (21.6) | 22 (16.5) | 10 (30.3) | 0.4216 |
| Previous PCI only (%) | 160 (15.7) | 134 (15.8) | 17 (12.7) | 9 (27.3) | 0.8681 |
| Previous CABG only (%) | 33 (3.2) | 29 (3.4) | 3 (2.3) | 1 (3.0) | 0.4735 |
| Previous PCI and CABG (%) | 22 (2.2) | 20 (2.4) | 2 (1.5) | - (0) | 0.3334 |
| Previous MI (%) | 217 (21.3) | 186 (21.9) | 20 (15.0) | 11 (33.3) | 0.2825 |
| CHF (%) | 169 (16.6) | 158 (18.6) | 8 (6.0) | 3 (9.1) | 0.0001 |
| Total Cholesterol mg/dl (mean ± standard deviation) | 200.5 ± 51.3 | 204.8 ± 50.8 | 173.4 ± 46.3 | 172.9 ± 48.5 | <0.0001 |
| Cholesterol HDL mg/dl (mean ± standard deviation) | 39.9 ± 10.2 | 39.5 ± 10.1 | 42.2 ± 9.8 | 44.7 ± 13.1 | <0.0001 |
| Cholesterol LDL mg/dl (mean ± standard deviation) | 118.8 ± 28.3 | 118.7 ± 26.8 | 119.9 ± 36.2 | 116.6 ± 37.4 | <0.0001 |
| Triglyceride mg/dl (mean ± standard deviation) | 129.9 ± 46.5 | 129.8 ± 43.4 | 132.3 ± 67.5 | 124.7 ± 41.2 | <0.0001 |
| Serum Creatinine mg/dl (mean ± standard deviation) | 1.23 ± 0.98 | 1.26 ± 1.02 | 1.0 ± 0.3 | 1.2 ± 1.36 | 0.0001 |
STEMI ST-elevation myocardial infarction; NSTEMI Non-ST elevation myocardial infarction; CAD coronary artery disease; FFR fractional flow reserve; IVUS intravascular ultrasound; PCI percutaneous coronary intervention; CABG coronary artery bypass grafting; CHF congestive heart failure; HDL high density lipoprotein; LDL low density lipoprotein.
Patients with suspected stable ischemic heart disease and secondary outcomes.
| Variable | Appropriate n = 69 (37.7%) | Uncertain n = 94 (51.4%) | Inappropriate n = 20 (10.9%) | P Value* |
|---|---|---|---|---|
| No Prior Noninvasive Testing n = 33 (%) | 13 (18.8) | 9 (9.6) | 11 (55) | 0.8250 |
| - Asymptomatic, n = 10, (%) | - (0) | 2 (2.2) | 8 (40) | 0.0114 |
| - Symptomatic, n = 23, (%) | 13 (18.8%) | 7 (7.4%) | 3 (15) | 0.0464 |
| Prior Noninvasive Testing, n = 150, (%) | 56 (81.2) | 85 (90) | 9 (45) | 0.8250 |
| - ECG Stress Testing, n = 120, (%) | 42 (60.9) | 73 (77.7) | 5 (25) | 0.2974 |
| Low-risk findings (Duke t.s. ≥ 5%) n = 9, (%) | - (0) | 4 (4.3) | 5 (25) | 0.0167 |
| Intermediate-risk findings (Duke t.s. 4 to −10%) n = 69, (%) | - (0) | 69 (73.4) | - (0) | <0.0001 |
| High-risk findings (Duke t.s. ≤ -11%) n = 42, (%) | 42 (60.9) | - (0) | - (0) | <0.0001 |
| - Stress Test with Imaging (SPECT MPI, Stress Echocardiography, CMR%), n = 20, (%) | 8 (11.6) | 9 (9.6) | 3 (15) | 0.8224 |
| Low-risk findings, n = 9, (%) | - (0) | 6 (6.4) | 3 (15) | 0.0167 |
| Intermediate-risk findings, n = 10, (%) | 7 (10.1) | 3 (3.2) | - (0) | 0.0302 |
| High-risk findings, n = 1, (%) | 1 (1.5) | - (0) | - (0) | 0.1974 |
| - Echocardiography, n = 7, (%) | 5 (7.2) | 2 (2.1) | - (0) | 0.0605 |
| - Coronary CTA, n = 3, (%) | 1 (1.5) | 1 (1.1) | 1 (5) | 0.8748 |
| Revascularization, n = 68, (%) | 40 (58) | 24 (25.5) | 4 (20) | <0.0001 |
| PCI, n = 60, (%) | 32 (46.4) | 24 (25.5) | 4 (20) | 0.0023 |
| CABG, n = 8, (%) | 8 (11.6) | - (0) | - (0) | 0.0002 |
ECG electrocardiogram; Duke t.s. Duke treadmill score; SPECT MPI single-photon emission computed tomography myocardial perfusion imaging; CMR stress cardiovascular magnetic resonance; CTA computed tomography angiography; PCI percutaneous coronary intervention; CABG coronary artery bypass grafting.
Diagnostic yield of angiography in the coronary artery disease subgroup according to appropriateness category.
| Variable | All Cases n = 1018 | Appropriate n = 848 (83.3%) | Uncertain n = 133 (13.1%) | Inappropriate n = 37 (3.6%) | P Value* |
|---|---|---|---|---|---|
| Normal coronaries (%) | 137 (13.5) | 89 (10.5) | 34 (25.5) | 14 (37.9) | <0.0001 |
| Not significant coronary disease (%) | 167 (16.4) | 115 (13.5) | 40 (30.1) | 12 (32.4) | <0.0001 |
| Critical coronary disease (%) | 714 (70.1) | 644 (75.9) | 59 (44.3) | 11 (29.7) | <0.0001 |
| Revascularization (PCI or CABG) (%) | 586 (57.6) | 535 (63.1) | 43 (32.3) | 8 (21.6) | <0.0001 |
| Critical coronary disease: PCI (%) | 561 (55.1) | 515 (60.7) | 38 (28.6) | 8 (21.6) | <0.0001 |
| Critical coronary disease: CABG (%) | 25 (2.4) | 20 (2.4) | 5 (3.8) | - (0) | 0.9961 |
| Critical coronary disease: medical therapy | 128 (12.6) | 109 (12.9) | 16 (7.5) | 3 (8.1) | 0.5472 |
| Number of diseased vessels (mean ± standard deviation) | 1.09 ± 1.02 | 1.16 ± 0.94 | 0.66 ± 0.87 | 0.43 ± 0.80 | 0.0007 |
| Total 3-vessel and LM disease (%9 | 162(15.9) | 149 (17.6) | 11 (8.3) | 2 (5.4) | 0.0012 |
| 3-vessel disease (%) | 101 (9.9) | 94 (11.1) | 6 (4.5) | 1 (2.7) | 0.0055 |
| LM disease (%) | 61 (6.0) | 55 (6.5) | 5 (3.8) | 1 (2.7) | 0.3406 |
| Jeopardy score (mean ± standard deviation) | 3.8 ± 3.97 | 4.44 ± 3.93 | 2.63 ± 3.79 | 2.16 ± 3.81 | 0.0023 |
PCI percutaneous coronary intervention; CABG coronary artery bypass grafting; LM Left Main.
Multivariate logistic regression for the appropriateness rate according to the AUC.
| Variable | p-value | OR | 95% CI |
|---|---|---|---|
| Jeopardy Score | 0.883 | 0.995 | 0.927–1.067 |
| Male Sex | 0.712 | 0.903 | 0.525–1.553 |
| Tobacco Use | 0.357 | 0.965 | 0.634–1.178 |
| Diabetes mellitus | 0.960 | 1.014 | 0.585–1.757 |
| Hypertension history | 0.521 | 1.223 | 0.661–2.264 |
| Hypercholesterolemia | 0.214 | 0.704 | 0.404–1.224 |
| Chronic Obstructive Pulmonary Disease | 0.547 | 1.390 | 0.475–4.068 |
| Kidney disease | 0.902 | 1.041 | 0.545–1.990 |
| Congestive Heart failure | 0.0001 | 7.640 | 3.441–16.961 |
| Past Myocardial infarction | 0.821 | 1.073 | 0.583–1.975 |
| Serum Creatinine | 0.750 | 0.939 | 0.639–1.380 |
| Triglyceride | 0.304 | 0.998 | 0.994–1.002 |
| Total Cholesterol | 0.031 | 1.015 | 1.001–1.030 |
| HDL | 0.011 | 0.980 | 0.964–0.995 |
| LDL | 0.533 | 0.992 | 0.966–1.018 |
| Acute Coronary Syndrome | 0.0001 | 14.900 | 6.840–32.460 |
| Constant | 0.101 | 3.671 |
The model as a whole explained between 21% (Cox and Snell R square) and 41% (Nagelkerke R square) of the variance in the appropriateness rate according to the AUC, and correctly classified 89% of cases.